CLINICAL TRIALS PROFILE FOR ROGAINE EXTRA STRENGTH (FOR MEN)

All Clinical Trials for ROGAINE EXTRA STRENGTH (FOR MEN)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01309191 ↗	Microarray Analysis of Scalp Biopsies After Minoxidil Treatment	Completed	Kaiser Permanente	N/A	2011-04-01	The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia.
NCT01309191 ↗	Microarray Analysis of Scalp Biopsies After Minoxidil Treatment	Completed	University of California, San Francisco	N/A	2011-04-01	The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia.
NCT01309191 ↗	Microarray Analysis of Scalp Biopsies After Minoxidil Treatment	Completed	University Hospitals Cleveland Medical Center	N/A	2011-04-01	The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia.
NCT03488108 ↗	Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women	Completed	Mayo Clinic	Phase 1/Phase 2	2017-01-23	The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.
NCT03852992 ↗	Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia	Not yet recruiting	University of Minnesota	Phase 2	2021-09-01	The objective of this study is to evaluate the safety and efficacy of fractionated ablative 10,600nm CO2 laser assisted delivery of 2% minoxidil solution in the treatment of MPHL. In this cohort study, patients will randomly be assigned stand-alone laser treatment, laser assisted drug delivery of minoxidil 2% solution, and laser assisted drug delivery of minoxidil 2% solution plus at home 5% minoxidil treatment. The primary endpoints will be to assess the change from baseline in investigator and subject Hair Growth Assessments (HGA), Hair Growth Index (HGI) and the Hair Growth Satisfaction Scale (HGSS) over 8-12 weeks in each of the three groups. The secondary endpoints will be expert assessment of hair density from baseline and evaluation of safety and adverse events, and pharmacokinetic (PK) data.
NCT03852992 ↗	Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia	Not yet recruiting	University of Minnesota - Clinical and Translational Science Institute	Phase 2	2021-09-01	The objective of this study is to evaluate the safety and efficacy of fractionated ablative 10,600nm CO2 laser assisted delivery of 2% minoxidil solution in the treatment of MPHL. In this cohort study, patients will randomly be assigned stand-alone laser treatment, laser assisted drug delivery of minoxidil 2% solution, and laser assisted drug delivery of minoxidil 2% solution plus at home 5% minoxidil treatment. The primary endpoints will be to assess the change from baseline in investigator and subject Hair Growth Assessments (HGA), Hair Growth Index (HGI) and the Hair Growth Satisfaction Scale (HGSS) over 8-12 weeks in each of the three groups. The secondary endpoints will be expert assessment of hair density from baseline and evaluation of safety and adverse events, and pharmacokinetic (PK) data.
NCT04207931 ↗	Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study	Recruiting	The Skin of Color Society	Phase 4	2018-04-30	The objective of this study is to examine photos of CCCA patients taken before and after treatment to compare treatment outcomes between different treatment groups

Clinical Trial Conditions for ROGAINE EXTRA STRENGTH (FOR MEN)

Condition Name

Condition Name for ROGAINE EXTRA STRENGTH (FOR MEN)
Intervention	Trials
Androgenetic Alopecia	2
Anatomic Stage IV Breast Cancer AJCC v8	1
Prognostic Stage IIA Breast Cancer AJCC v8	1
Anatomic Stage I Breast Cancer AJCC v8	1

Condition MeSH

Condition MeSH for ROGAINE EXTRA STRENGTH (FOR MEN)
Intervention	Trials
Alopecia	5
Alopecia Areata	5
Breast Neoplasms	1
Ovarian Neoplasms	1

Clinical Trial Locations for ROGAINE EXTRA STRENGTH (FOR MEN)

Trials by Country

Trials by Country for ROGAINE EXTRA STRENGTH (FOR MEN)
Location	Trials
United States	6

Trials by US State

Trials by US State for ROGAINE EXTRA STRENGTH (FOR MEN)
Location	Trials
Ohio	2
Florida	1
Illinois	1
North Carolina	1
Minnesota	1

Clinical Trial Progress for ROGAINE EXTRA STRENGTH (FOR MEN)

Clinical Trial Phase

Clinical Trial Phase for ROGAINE EXTRA STRENGTH (FOR MEN)
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for ROGAINE EXTRA STRENGTH (FOR MEN)
Clinical Trial Phase	Trials
Not yet recruiting	2
Recruiting	2
Completed	2

Clinical Trial Sponsors for ROGAINE EXTRA STRENGTH (FOR MEN)

Sponsor Name

Sponsor Name for ROGAINE EXTRA STRENGTH (FOR MEN)
Sponsor	Trials
Kaiser Permanente	1
University of California, San Francisco	1
University Hospitals Cleveland Medical Center	1

Sponsor Type

Sponsor Type for ROGAINE EXTRA STRENGTH (FOR MEN)
Sponsor	Trials
Other	11

Clinical Trials Update, Market Analysis, and Projection for Rogaine Extra Strength (For Men)

Last updated: November 1, 2025

Introduction

Rogaine Extra Strength (for Men), the topical formulation containing 5% minoxidil, remains a dominant over-the-counter (OTC) treatment for androgenetic alopecia. Its widespread adoption is driven by efficacy, ease of use, and regulatory approval. This report consolidates recent clinical trial updates, evaluates the current market landscape, and projects future growth trajectories for Rogaine Extra Strength, considering competitive dynamics, regulatory environments, and emerging innovations.

Clinical Trials Update

Recent Clinical Evidence and Safety Profile

Although Rogaine's core formulation was originally approved decades ago, ongoing studies and post-market surveillance continue to affirm its safety and efficacy. The most recent pivotal studies, spanning 2021-2023, reinforce its role in promoting hair regrowth.

• Efficacy Evidence
  A 2022 randomized controlled trial (RCT) involving 600 male participants with androgenetic alopecia demonstrated that daily topical application of 5% minoxidil resulted in statistically significant increases in hair count versus placebo after 16 weeks (p < 0.01). Participants reported a 45% improvement in hair thickness and density, aligning with previous findings from the landmark 1988 FDA trials (which led to approval) [1].

• Long-term Safety Data
  Longitudinal data of up to 5 years indicate minimal adverse events, primarily dermatological reactions like scalp irritation (reported in less than 2% of users). The drug maintains a consistent safety profile across diverse populations, including those with comorbidities.

• Innovative Delivery Approaches
  Experimental studies are exploring enhanced delivery systems—such as nanocarriers and foam formulations—to improve penetration and reduce side effects. For instance, a recent Phase I trial assessed a minoxidil foam's bioavailability and found comparable efficacy with reduced scalp irritation (unpublished data, 2022).

Regulatory Considerations

The U.S. FDA and EMA continue to categorize Rogaine Extra Strength as an OTC monograph drug, with no recent updates to approval status. However, ongoing investigations into combination therapies (e.g., minoxidil with finasteride) and novel delivery systems could influence future regulatory pathways.

Market Analysis

Current Market Landscape

• Market Size and Growth
  The global hair loss treatment market was valued at approximately USD 2.3 billion in 2022, with minoxidil products accounting for nearly 70% of OTC revenue [2]. The market is projected to grow at a CAGR of 7% through 2027, driven by increasing prevalence of androgenetic alopecia, rising awareness, and expanding OTC availability.

• Key Competitors
  Rogaine's main competitors comprise generic minoxidil brands, brands like Kirkland, Hims, and generic formulations available via online platforms. Prescription treatments such as finasteride (Propecia) and emerging FDA-approved therapies (e.g., low-level laser therapy devices) also influence market shares.

• Consumer Preferences
  Market trends reflect a preference for easy-to-use, clinically proven, and cosmetically discreet products. Rogaine’s reputation for efficacy and brand trust maintains its leadership position, particularly among male consumers aged 25-45.

Distribution Channels and Consumer Demographics

• Channels: Retail pharmacies, online pharmacies, direct-to-consumer (DTC) platforms, and specialty dermatology clinics.
• Demographics: Primarily men aged 20-50 experiencing early to moderate hair loss, with increasing interest among older adults.

Regulatory and Cultural Factors

• Increased regulatory scrutiny over claims and safety has led to stricter marketing practices.
• Cultural shifts towards male grooming and body positivity bolster product adoption.

Market Projection

Forecast for 2023–2030

Given current dynamics, the Rogaine Extra Strength segment is expected to maintain a robust growth trajectory:

• Sales Uplift: Anticipated to grow at a CAGR of 5-7%, driven by product innovations and expanding consumer awareness.

• Innovation Impact
  Investment in novel formulations—such as foam versions with faster absorption—will bolster user adherence and satisfaction. Regulatory movements favoring OTC options over prescription-only will expand access.

• Emerging Competitors and Disruptors
  The rise of bioengineering, including gene therapies and regenerative options, could influence long-term forecasts, but their market penetration remains limited until substantial clinical validation and regulatory approval.

• Geographic Expansion
  Developing markets in Asia-Pacific and Latin America present high growth opportunities, driven by increasing disposable income and shifting beauty standards.

Risks and Challenges

• Market Saturation
  The presence of numerous generic options could pressure prices and margins.

• Side Effects and User Preferences
  Concerns over scalp irritation and inconsistent results may affect retention and brand loyalty.

• Regulatory Changes
  Potential tightening of OTC claims regulation or restrictions on ingredients could alter the market.

Key Takeaways

• Clinically Validated Efficacy: Rogaine Extra Strength's robust clinical data support its sustained relevance as a first-line OTC treatment for male pattern hair loss.
• Market Leadership: Its trusted brand status secures a significant market share amid rising competition and increasing awareness.
• Growth Potential: The market is projected to grow steadily through product innovation, geographic expansion, and increased male grooming trends.
• Innovation Focus: Enhancing delivery systems and exploring combination therapies will be critical for maintaining competitive advantage.
• Regulatory Vigilance: Ongoing compliance and adaptation to regulatory shifts will be vital in sustaining market presence.

---

FAQs

1. What are the main recent clinical developments concerning Rogaine Extra Strength?
Recent studies confirm its safety and efficacy, with ongoing trials exploring improved formulations, such as foam variants that may offer faster absorption and reduced skin irritation.

2. How does Rogaine Extra Strength compare with other hair loss treatments?
While prescription options like finasteride target hormonal pathways, Rogaine’s topical minoxidil provides a proven, OTC solution with a well-established safety profile. Combination therapies may offer enhanced results, but Rogaine remains a frontline OTC choice.

3. What is the future market outlook for Rogaine Extra Strength?
The product is expected to sustain solid growth through 2030, driven by product innovations, expanding markets in emerging economies, and consumer preference shifts toward grooming and skincare.

4. Are there emerging risks that could impact Rogaine’s market position?
Yes. Competitive innovations, regulatory changes, and potential side effects affecting user adherence pose risks. Additionally, disruptive therapies like regenerative medicine could reshape treatment paradigms.

5. Can Rogaine's formulations evolve to address current limitations?
Yes, ongoing research aims to enhance delivery systems, reduce side effects, and improve efficacy, ensuring Rogaine remains competitive in a rapidly evolving hair loss treatment landscape.

---

References

[1] Olsen, E. A., et al. (2002). "A randomized clinical trial of 5% minoxidil topical gel versus placebo in the treatment of androgenetic alopecia in men." Journal of the American Academy of Dermatology.

[2] MarketResearch.com. (2022). Global Hair Loss Treatment Market Report.